Showing Results for
From:Journal of Experimental & Clinical Cancer Research (Vol. 38, Issue 1) Peer-ReviewedBackground Previous studies showed that the combination of an anti-Epidermal growth factor (EGFR) and a MEK-inhibitor is able to prevent the onset of resistance to anti-EGFR monoclonal antibodies in KRAS-wild type...
From:Journal of Experimental & Clinical Cancer Research (Vol. 38, Issue 1) Peer-ReviewedBackground Targeting the epidermal growth factor receptor (EGFR) either alone or in combination with chemotherapy is an effective treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC)....
From:Journal of Experimental & Clinical Cancer Research (Vol. 40, Issue 1) Peer-ReviewedBackground Despite the advancements in new therapies for colorectal cancer (CRC), chemotherapy still constitutes the mainstay of the medical treatment. For this reason, new strategies to increase the efficacy of...
From:Medical Oncology (Vol. 38, Issue 3) Peer-ReviewedAbstract Only
Choose how you want to be alerted when new results for your search become available.
Subscribe to Gale's RSS feed to get content delivered to your favorite RSS aggregator. Copy and paste the URL below into your reader:
Tell us where to send the alert and how often you want to receive it